| Dennis M Lindeborg, MD | |
|
9961 Sierra Ave, Fontana, CA 92335-6720 | |
| (909) 427-3910 | |
| Not Available |
| Full Name | Dennis M Lindeborg |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 9961 Sierra Ave, Fontana, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649341694 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | G67683 (California) | Primary |
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316979834 PECOS PAC ID: 6002729175 Enrollment ID: O20040126000823 |
News Archive
Tuberculosis (TB) is a highly infectious disease and a major global health problem, especially in countries with developing health care systems. Because there is no fast, easy way to detect TB, the deadly infection can spread quickly through communities. Now, a team reports in ACS Sensors the development of a rapid, sensitive and low-cost method for detecting the disease in resource-limited areas.
Masimo, the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, today announced that the U.S. Department of Homeland Security recently issued a Federal warning about the increased risk of carbon monoxide exposure during the winter season—urging heightened awareness and precaution for firefighters, who are at increased risk of duty-related CO danger. The life-threatening consequences of CO poisoning make immediate detection, helped by the noninvasive Masimo Rad-57 Pulse CO-Oximeter, a lifesaving necessity for fire and emergency operations.
A new use of the drug Herceptin appears to offer a much more powerful treatment advantage than expected for patients with HER-2-positive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dennis M Lindeborg, MD 9961 Sierra Ave, Fontana, CA 92335-6720 Ph: (909) 427-3910 | Dennis M Lindeborg, MD 9961 Sierra Ave, Fontana, CA 92335-6720 Ph: (909) 427-3910 |
News Archive
Tuberculosis (TB) is a highly infectious disease and a major global health problem, especially in countries with developing health care systems. Because there is no fast, easy way to detect TB, the deadly infection can spread quickly through communities. Now, a team reports in ACS Sensors the development of a rapid, sensitive and low-cost method for detecting the disease in resource-limited areas.
Masimo, the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, today announced that the U.S. Department of Homeland Security recently issued a Federal warning about the increased risk of carbon monoxide exposure during the winter season—urging heightened awareness and precaution for firefighters, who are at increased risk of duty-related CO danger. The life-threatening consequences of CO poisoning make immediate detection, helped by the noninvasive Masimo Rad-57 Pulse CO-Oximeter, a lifesaving necessity for fire and emergency operations.
A new use of the drug Herceptin appears to offer a much more powerful treatment advantage than expected for patients with HER-2-positive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.
› Verified 7 days ago
Loc Nguyen, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Department Of Anesthesia, Fontana, CA 92335 Phone: 602-615-9226 | |
Ricardo P. Diaz, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Sharon S. Sung, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Batool Hajianpour, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Narendra Trivedi, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Dr. Steven John D'sa, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-302-4938 | |
Amgad Hanna Nashid Hanna, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 877-608-0044 |